Introduction: Who Should Undergo Diagnostics and When

If you’ve been experiencing changes in your bowel habits, noticed blood in your stool, or have persistent abdominal discomfort that doesn’t go away, it may be time to talk to a healthcare provider about diagnostic testing. These symptoms can be signs of many conditions, including colorectal cancer, but they should always be checked out to determine the cause.^[1]

People who have gone through initial screening tests that showed abnormal results, such as blood in the stool or suspicious findings during a routine examination, will typically need more detailed diagnostic procedures. Additionally, if you’re at higher risk for colorectal cancer due to family history, previous polyps, or certain genetic conditions, your doctor may recommend more frequent or earlier diagnostic testing.^[3]

The goal of diagnostics is not only to identify whether cancer is present but also to understand its characteristics and extent. This information helps your medical team determine the stage of the disease and plan the most appropriate treatment approach. Stage II colorectal cancer specifically means the cancer has grown into the outer layers of the colon or rectum but has not yet spread to lymph nodes or distant organs.^[1]

Diagnostic Methods for Identifying Stage II Colorectal Cancer

Several classic diagnostic methods are used to identify colorectal cancer and distinguish stage II disease from other stages. Each test provides different information that helps create a complete picture of your health situation.

Colonoscopy and Tissue Examination

A colonoscopy is one of the most important diagnostic tools for colorectal cancer. During this procedure, a flexible tube with a camera is gently inserted through the rectum to view the inside of your entire large bowel. The doctor can see the lining of your colon in real time and identify any abnormal growths, ulcers, or areas of concern.^[3]

If suspicious areas are found during colonoscopy, the doctor can take small tissue samples, called biopsies, right away. These samples are then examined under a microscope by a specialist called a pathologist. The pathologist looks at the cells to determine whether cancer is present and what type of cancer it is. This microscopic examination is essential because it confirms the diagnosis and provides information about how aggressive the cancer cells appear.^[6]

Sometimes cancer is discovered when a polyp is removed during a colonoscopy. If the pathology report shows cancer cells in that polyp, additional surgery may be needed, or in some cases, the removal of the polyp itself may be sufficient treatment if the cancer was completely contained and removed.^[1]

Imaging Studies

Computed tomography scans, commonly called CT scans, create detailed three-dimensional images of your body using X-rays taken from multiple angles. For colorectal cancer, CT scans of the chest, abdomen, and pelvis help doctors see whether the tumor has grown through the colon wall and whether it has spread to nearby organs, lymph nodes, or distant sites like the liver or lungs.^[3]

In stage II colorectal cancer, CT scans are particularly important because they help confirm that the cancer has not spread to lymph nodes or other organs. This distinction separates stage II from stage III disease, which involves lymph node spread, and stage IV disease, which involves distant organ spread.^[7]

Magnetic resonance imaging, or MRI, uses powerful magnets and radio waves instead of radiation to create detailed pictures of soft tissues. MRI is especially useful for rectal cancer because it can show very clearly how deep the tumor has grown into the rectal wall and whether it has reached nearby structures. This information is crucial for planning treatment, particularly for rectal cancer located in the back passage.^[6]

Understanding the TNM Staging System

Doctors use a system called TNM staging to describe how far the cancer has spread. The letters stand for Tumor, Node, and Metastasis. The T describes how deeply the tumor has grown into the layers of the colon or rectum wall. The N tells whether cancer cells are found in nearby lymph nodes. The M indicates whether the cancer has spread to distant organs.^[7]

For stage II colorectal cancer, the designation is T3 or T4, N0, M0. This means the tumor has grown quite deeply into or through the colon wall (T3 or T4), but there is no cancer in the lymph nodes (N0) and no distant spread (M0). Stage II is further divided into three subcategories based on how far the tumor has grown.^[6]

In stage IIA, the cancer has grown into the thick outer muscle layer of the colon, called the muscularis propria, but has not grown beyond it. In stage IIB, the tumor has grown through the muscle layer and reached the outermost covering of the colon, called the serosa. In stage IIC, the cancer has grown through the colon wall entirely and touched or grown into nearby tissues or organs.^[1]

Lymph Node Examination

An important part of diagnosing stage II colorectal cancer is examining lymph nodes near the tumor. During surgery to remove the cancer, the surgeon also removes nearby lymph nodes. The pathologist then examines these nodes under a microscope to look for cancer cells.^[4]

Medical guidelines recommend that at least twelve lymph nodes should be removed and examined. This number is important because if fewer than twelve nodes are checked, there’s a higher chance that cancer in the lymph nodes might be missed. When fewer than twelve nodes are examined, even if they all appear cancer-free, doctors consider this a high-risk feature that may influence treatment decisions.^[4]

Laboratory Blood Tests

Blood tests provide additional information that helps with diagnosis and treatment planning. A test called CEA, which stands for carcinoembryonic antigen, measures a protein that is sometimes elevated in people with colorectal cancer. While not all people with colorectal cancer have elevated CEA levels, this test can be useful for monitoring treatment response and watching for cancer recurrence after treatment.^[21]

Standard blood tests also check your overall health, including your red blood cell count, liver function, and kidney function. These results help doctors understand whether you’re healthy enough for surgery or other treatments and whether the cancer has affected other organs.^[3]

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or combinations of treatments for cancer. For patients with stage II colorectal cancer, some clinical trials may be available, and specific diagnostic tests are used to determine whether someone qualifies to participate.

Molecular and Genetic Testing

One of the most important tests for clinical trial qualification and treatment planning is microsatellite instability testing, often abbreviated as MSI. Microsatellites are short, repeated sequences of DNA, and microsatellite instability occurs when cells cannot properly repair mistakes in DNA copying. Tumors with high microsatellite instability, called MSI-H, behave differently from other colorectal cancers and may respond better to certain treatments, particularly immunotherapy.^[4]

Related to MSI testing is testing for something called mismatch repair deficiency, or dMMR. Mismatch repair proteins normally fix DNA copying errors, and when these proteins don’t work properly, it leads to MSI. Testing tumor tissue for the presence or absence of these proteins helps classify the cancer and guide treatment decisions. Many clinical trials specifically enroll patients based on their MSI or MMR status.^[4]

Understanding your tumor’s biomarker status is increasingly important. Biomarkers are biological characteristics of the tumor cells that can be measured through testing. Beyond MSI and MMR status, other biomarkers may be tested depending on the specific clinical trial. These might include genetic mutations in genes like KRAS, NRAS, or BRAF, which can affect how tumors respond to certain targeted therapies.^[4]

Risk Stratification Features

Clinical trials often enroll patients based on their risk level for cancer recurrence. Several features help doctors classify stage II colorectal cancer into low-risk, intermediate-risk, or high-risk categories. High-risk features include tumors that are classified as T4, meaning they’ve grown through the colon wall into nearby structures; examination of fewer than twelve lymph nodes; tumors that have grown into blood vessels or lymphatic vessels; tumors that have grown into the spaces around nerves; and tumors that are poorly differentiated or high-grade, meaning the cancer cells look very abnormal under the microscope.^[4]

Additional high-risk features include bowel obstruction (when the tumor blocks the intestine) or bowel perforation (when the tumor causes a hole in the colon wall). If cancer cells are found at the edge of the tissue removed during surgery, meaning the margins weren’t completely clear, this is also considered high-risk.^[11]

Emerging Diagnostic Tools

Newer diagnostic approaches are being studied in clinical trials. One emerging tool is called Immunoscore, which measures the immune system’s response to the tumor by looking at the types and locations of immune cells within and around the cancer. Early research suggests this scoring system might help predict which patients are at higher risk for recurrence and who might benefit from additional treatment after surgery.^[4]

Another promising area is testing for circulating tumor DNA, abbreviated as ctDNA. This involves looking for tiny fragments of tumor DNA that can be found in the bloodstream. After surgery to remove the tumor, the presence of ctDNA might indicate that microscopic cancer cells remain in the body, even though no visible cancer is seen on scans. This test is being studied to help personalize treatment decisions and identify patients who need additional therapy.^[4]

Pre-Treatment Health Assessment

Before enrolling in a clinical trial or starting any treatment, doctors need to assess your overall health status and any other medical conditions you have, called comorbidities. This includes evaluating your heart function, kidney function, and ability to tolerate chemotherapy if it’s being considered. Some clinical trials have specific requirements about how healthy participants need to be.^[4]

For patients who might receive certain chemotherapy drugs, testing for an enzyme called dihydropyrimidine dehydrogenase, or DPD, is recommended in many countries. People with DPD deficiency can have severe, even life-threatening reactions to fluoropyrimidine chemotherapy drugs like 5-fluorouracil or capecitabine. Testing before treatment helps prevent these serious complications.^[4]